65,437 trials
Pacemaker Indication
Primary: Efficacy of Atrial Capture Control Feature (Automatic Atrial Threshold Test Minus Manual Atrial Measurement) — -0.01 Volt
Hypophosphatasia (HPP)
Primary: Change in Rickets Severity From Baseline to Week 24, Based on Assessment of Skeletal Radiographs Using Radiologic Global Impression of Change (RGI-C) — 2.00 Units on a…
Rheumatoid Arthritis
Primary: Disease Activity Score in 28 Joints (DAS28) Based on Erythrocyte Sedimentation Rate (ESR) — 6.0; 3.3; 3.1; 3.0 units on a scale
Head and Neck Cancer
Primary: Overall Survival Time (OS) — 10.1; 7.4 months — p=0.036
Sleep Initiation and Maintenance Disorders
Primary: Pain — 3.72; 5.41 scores on a scale
Rheumatoid Arthritis
Primary: Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78…
Respiratory Tract Diseases · Lung Diseases · Lung Diseases, Interstitial
Primary: Minimal/no Progression (1 yr) by High Resolution Computed Tomography (HRCT) & Pulmonary Function — 12 Participants
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Melanoma
Primary: Progression-free Survival — 4.2; 5.6 months
Non-Small Cell Lung Cancer
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy — 500; 20; 500; 75 milligrams per square meter (mg/m^2)
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
Arthritis, Rheumatoid
Primary: American College of Rheumatology (ACR) 20 Response at Week 14. — 27; 51; 54; 105 participants — p=<0.001
Acute Coronary Syndrome
Primary: Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI) — 14.7; 15.7; 0.6; 0.6…
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants
Chemotherapy-induced Nausea and Vomiting (CINV)
Primary: Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1 — 0.696; 0.570…